Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application

Journal of Immunotherapy

Volumn 35, Issue 5, 2012, Pages 430-439

  Zhang, Ling ^a   Feldman, Steven A ^a   Zheng, Zhili ^a   Chinnasamy, Nachimuthu ^a   Xu, Hui ^a   Nahvi, Azam V ^a   Dudley, Mark E ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive T cell therapy; IL 12; NFAT responsive promoter

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HLA A2 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; MELAN A; OKT 3; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; EFFECTOR CELL; EVALUATION; GENE EXPRESSION; GENE INSERTION; GENETIC ENGINEERING; HLA MATCHING; HUMAN; HUMAN CELL; METASTATIC MELANOMA; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; SUPERNATANT; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADOPTIVE TRANSFER; COCULTURE TECHNIQUES; GAMMARETROVIRUS; GENE EXPRESSION; GENETIC VECTORS; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTORS, ANTIGEN, T-CELL; TRANSDUCTION, GENETIC;

EID: 84861229798     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31825898e8     Document Type: Article

References (24)

1. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13:4677-4685. (Pubitemid 47294773)
2. Kerkar SP, Muranski P, Kaiser A, et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010;70:6725-6734.
3. Cohen. J. IL-12deaths: explanation and a puzzle. Science. 1995;270:908.
4. Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;4:751-759.
5. Xu W, Russ JL, Eiden MV. Evaluation of residual promoter activity in gamma-retroviral self-inactivating (SIN) vectors. Mol Ther. 2012;20:84-90.
6. Ozturk F, Park PJ, Tellez J, et al. Expression levels of the PiT2 receptor explain, in part, the gestational age-dependent alterations in transduction efficiency following in utero retroviralmediated gene transfer. J Gene Med. 2012;14:169-181.
7. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108:2545-2553.
8. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
9. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646-2655.
10. Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122-6131.
11. Hooijberg E, Bakker AQ, Ruizendaal JJ, et al. NFAT-controlled expression of GFP permits visualization and isolation of antigenstimulated primary human T cells. Blood. 2000;96:459-466. (Pubitemid 30463363)
12. Schambach A, Galla M, Maetzig T, et al. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther. 2007;15:1167-1173. (Pubitemid 46813620)
13. Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 2010;184:5988-5998.
14. Riddell SR, Greenberg. PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201. (Pubitemid 20120262)
15. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472. (Pubitemid 40647143)
16. Feldman SA, Goff SL, Xu H, et al. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. Hum Gene Ther. 2011;22: 107-115.
17. Onodera M, Yachie A, Nelson DM, et al. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther. 1997;8:1189-1194. (Pubitemid 27394127)
18. FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research. Guidance for industry: INDs-Approaches to Complying with cGMP during Phase I (Draft). Rockville, MD: FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research; 2006.
19. FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. Rockville, MD: FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research; 1998.
20. FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research. Reference Point to Consider in the Production and Testing of New Drug and Biologicals Produced by Recombinant DNA Technology. Rockville, MD: FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research; 1985.
21. FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research. Points to Consider in the Use of Cell Lines to Produce Biologicals. Rockville, MD: FDA US Department of Health and Human Service, Center for Drug Evaluation and Research, Center for Biologic Evaluation and Research; 1993.
22. Herzog RW. Gene therapy for SCID-X1: round 2. Mol Ther. 2010;18:1891.
23. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol. 2007;34:524-531. (Pubitemid 350236303)
24. Leonard JP, Sherman ML, Fisher GL, et al. Effects of singledose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90: 2541-2548. (Pubitemid 27413462)